Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent

Journal of the American Academy of Dermatology

Volumn 75, Issue 3, 2016, Pages 612-618.e6

  Yamauchi, Paul S ^a,b   Bissonnette, Robert ^c   Teixeira, Henrique D ^d   Valdecantos, Wendell C ^d  

^a Skin Care Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INNOVADERM RESEARCH   (Canada)

^d ABBVIE INC   (United States)

Author keywords

adalimumab; etanercept; failure; infliximab; psoriasis; switching; tumor necrosis factor antagonist

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFECTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; SYSTEMATIC REVIEW; ADULT; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; MIDDLE AGED; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROGNOSIS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962488351     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.02.1221     Document Type: Review

References (25)

1. Leonardi, C.L., Powers, J.L., Matheson, R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003), 2014–2022.
2. Menter, A., Gordon, K.B., Leonardi, C.L., Gu, Y., Goldblum, O.M., Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 63 (2010), 448–456.
3. Menter, A., Tyring, S.K., Gordon, K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
4. Papp, K.A., Tyring, S., Lahfa, M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005), 1304–1312.
5. Reich, K., Nestle, F.O., Papp, K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005), 1367–1374.
6. Saurat, J.H., Stingl, G., Dubertret, L., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008), 558–566.
7. Gottlieb, A.B., Chaudhari, U., Baker, D.G., Perate, M., Dooley, L.T., The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2 (2003), 260–266.
8. Papp, K., Ho, V., Teixeira, H.D., Guerette, B., Chen, K., Lynde, C., Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicenter, phase IIIb study. J Eur Acad Dermatol Venereol 26 (2012), 1007–1013.
9. Gottlieb, A.B., Kalb, R.E., Blauvelt, A., et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol 67 (2012), 642–650.
10. Haitz, K.A., Kalb, R.E., Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 57 (2007), 120–125.
11. Woolf, R.T., Smith, C.H., Robertson, K., Barker, J.N., Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 163 (2010), 889–892.
12. van Lümig, P.P., Lecluse, L.L., Driessen, R.J., et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 163 (2010), 838–846.
13. Fonseca, E., Iglesias, R., Paradela, S., Fernandez-Torres, R.M., Elberdin, L., Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting. J Dermatolog Treat 26 (2015), 217–222.
14. Strober, B.E., Poulin, Y., Kerdel, F.A., et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 64 (2011), 671–681.
15. Bissonnette, R., Bolduc, C., Poulin, Y., Guenther, L., Lynde, C.W., Maari, C., Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 63 (2010), 228–234.
16. Bissonnette, R., Maari, C., Barber, K., Lynde, C.W., Vender, R., Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. J Eur Acad Dermatol Venereol 29 (2015), 1576–1581.
17. Vender, R., An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. J Drugs Dermatol 10 (2011), 396–402.
18. Ortonne, J.P., Chimenti, S., Reich, K., et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumor necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 25 (2011), 1012–1020.
19. Yamauchi, P.S., Mau, N., Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol 61 (2009), 158–160.
20. Martyn-Simmons, C.L., Green, L., Ash, G., Groves, R.W., Smith, C.H., Barker, J.N., Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 23 (2009), 1394–1397.
21. Piaserico, S., Cazzaniga, S., Chimenti, S., et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol 70 (2014), 257–262.e3.
22. Ayala, F., Lambert, J., on behalf of the TANGO Study Group. Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: a multicenter, open-label trial (TANGO). J Dermatolog Treat 26 (2015), 304–311.
23. Shikiar, R., Willian, M.K., Okun, M.M., Thompson, C.S., Revicki, D.A., The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes, 4, 2006, 71.
24. Bombardieri, S., Ruiz, A.A., Fardellone, P., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46 (2007), 1191–1199.
25. Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S., Kupper, H., Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther, 12, 2010, R117.